Eli Lilly and Company announced a significant move to acquire Centessa Pharmaceuticals, a UK-based biopharmaceutical company specializing in neuroscience, in…
Read More
Dulaglutide Shows Promise in Stabilizing Coronary Plaques, Revolutionizing Cardiovascular Protection Beyond Diabetes Management
The intricate relationship between Type 2 diabetes (T2D) and cardiovascular health has long been a focal point of medical research.…
Read More
Biogen Acquires Apellis Pharmaceuticals for $5.6 Billion to Bolster Immunology and Rare Disease Portfolio
Biogen, a global biotechnology company renowned for its pioneering work in neuroscience, has announced a significant strategic acquisition of Apellis…
Read More
Teva Pharmaceutical Secures FDA Approval for Ponlimsi Biosimilar to Prolia, Advances Xolair Biosimilar Applications in US and EU
Teva Pharmaceutical has announced a significant milestone in its biosimilar portfolio with the U.S. Food and Drug Administration (FDA) granting…
Read More
The UK Must Supercharge Its Commercial Strategy to Boost Global Life Sciences Competitiveness
Off the northwestern coast of mainland Europe, an island nation with significant ambitions for its life sciences sector is navigating…
Read More
Groundbreaking Diagnostic Innovations Promise to Halve Endometriosis Diagnosis Delays, Yet Systemic Hurdles Persist
Endometriosis, a debilitating chronic inflammatory condition affecting an estimated 10% of reproductive-age women globally, continues to be plagued by a…
Read More
The Rise of Antibody-Drug Conjugates: Precision Oncology’s Evolving Frontier
Antibody-drug conjugates (ADCs) represent a significant leap forward in targeted cancer therapy, a sophisticated class of drugs that marries the…
Read More
Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Bolster Psychiatric and Neurological Pipeline
TOKYO, JAPAN & BOSTON, USA – March 30, 2026 – Otsuka Pharmaceutical Co., Ltd. announced today that its subsidiary, Otsuka…
Read More
MSD’s $6.7 Billion Acquisition of Terns Pharmaceuticals Signals a Bold Strategic Pivot in Oncology to Secure Future Growth
On March 25, Merck & Co. (MSD) announced a significant strategic move, acquiring Terns Pharmaceuticals for an estimated $6.7 billion…
Read More
The Crucial Role of Payload Linker Innovation in the Rapidly Expanding Antibody-Drug Conjugate Market
Combining the targeted precision of monoclonal antibodies with the potent destructive power of cytotoxic payloads, Antibody-Drug Conjugates (ADCs) represent a…
Read MoreYOU MAY HAVE MISSED
